Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 study

J. Begun, M.C. Dubinsky, P.M. Irving, X. Li, S. Howaldt, J. Pokrotnieks, K. Krueger, J. Laskowski, T. Lissoos, J. Milata, N. Morris, V. Arora, C. Milch, B.E. Sands

Research output: Contribution to journalMeeting Abstractpeer-review

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Cite this